Itrasia 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Itrasia 200 is effective against infections caused by dermatophytes, yeasts, and molds, including conditions such as onychomycosis, histoplasmosis, blastomycosis, aspergillosis, and candidiasis. The capsule formulation ensures optimal bioavailability when taken with food, enhancing absorption. Dosage and duration of therapy should be individualized based on the type and severity of infection, patient response, and clinical guidelines. Itrasia 200 should be used cautiously in patients with hepatic impairment, congestive heart failure, or those receiving concomitant medications metabolized via the cytochrome P450 system due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and elevated liver enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy. Itrasia 200 Capsule offers an effective treatment option for managing challenging fungal infections under medical supervision.